Bromfenac


Generic Medicine Info
Indications and Dosage
Ophthalmic
Postoperative ocular inflammation, Postoperative ocular pain
Adult: For the treatment of inflammation and reduction of pain in patients undergoing cataract surgery: As 0.07% or 0.09% (once-daily formulation) ophthalmic solution: Instil 1 drop into the affected eye(s) once daily beginning 1 day before surgery, continued on the day of surgery, and for the 1st 2 weeks of the postoperative period. As 0.075% ophthalmic solution: Instil 1 drop into the affected eye(s) bid beginning 1 day prior to surgery, continued on the day of surgery, and for the 1st 2 weeks of the postoperative period. As 0.09% (twice-daily formulation) ophthalmic solution: Instil 1 drop into the affected eye(s) bid, beginning the next day after surgery and continued for the 1st 2 weeks of the postoperative period.
Contraindications
Hypersensitivity to bromfenac or other NSAIDs. Patients in whom attacks of asthma, acute rhinitis, or urticaria are precipitated by aspirin or other agents with prostaglandin synthetase inhibiting activity.
Special Precautions
Patient with complicated ocular surgeries, corneal epithelial defects, corneal denervation, ocular surface diseases (e.g. dry eye syndrome), repeated ocular surgeries within a short period of time; diabetes mellitus, rheumatoid arthritis, predisposition to bleeding (e.g. known bleeding tendencies, receiving medicines which interfere with coagulation). May mask signs of acute ocular infection. Pregnancy and lactation.
Adverse Reactions
Significant: Corneal effects, including keratitis, epithelial breakdown, corneal thinning, erosion, perforation, or ulceration which may lead to loss of vision; increased intraocular bleeding (including hyphaema), delayed or slowed healing.
Eye disorders: Blurred vision, eye pain, eye irritation (including stinging/burning sensation), foreign body sensation in eyes, eye pruritus, eye redness, decreased visual acuity, corneal or eyelid oedema, photophobia, retinal exudates, iritis, ocular hypertension.
Nervous system disorders: Headache.
Patient Counseling Information
This drug may cause temporary blurring of vision, if affected, do not drive or operate machinery. Do not wear contact lenses during treatment.
Monitoring Parameters
Evaluate the patient’s allergy history with aspirin or other NSAIDs. Monitor for intraocular bleeding.
Drug Interactions
Concomitant use with ophthalmic corticosteroids may delay the healing of ophthalmic tissue and increase the risk of corneal adverse effects. May increase the risk of bleeding with drugs that prolong bleeding time.
Action
Description:
Mechanism of Action: Bromfenac, a phenylacetic acid derivative NSAID that inhibits prostaglandin synthesis in body tissues by reducing the activity of cyclooxygenase (COX) 1 and 2, thereby resulting in decreased formation of prostaglandin precursors.
Pharmacokinetics:
Absorption: Permeates efficiently into the cornea of cataract patients.
Distribution: Plasma protein binding: 99.8%.
Excretion: Elimination half-life: 1.4 hours (aqueous humour).
Chemical Structure

Chemical Structure Image
Bromfenac

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 60726, Bromfenac. https://pubchem.ncbi.nlm.nih.gov/compound/Bromfenac. Accessed Apr. 27, 2023.

Storage
Store between 15-25°C.
MIMS Class
Ophthalmic Decongestants, Anesthetics, Anti-Inflammatories
ATC Classification
S01BC11 - bromfenac ; Belongs to the class of non-steroidal antiinflammatory agents. Used in the treatment of inflammation of the eye.
References
Anon. Bromfenac. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 11/04/2023.

Anon. Bromfenac. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 11/04/2023.

Bromfenac Ophthalmic Solution 0.09% Solution/Drops (Alembic Pharmaceuticals Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 11/04/2023.

Bromsite 0.075% Solution/Drops (Sun Pharmaceutical Industries, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 11/04/2023.

Buckingham R (ed). Bromfenac Sodium. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/04/2023.

Joint Formulary Committee. Bromfenac. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/04/2023.

Prolensa Solution/Drops (Bausch & Lomb Incorporated). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 11/04/2023.

Yellox 0.9 mg/mL Eye Drops Solution (Bausch + Lomb Ireland Limited). MHRA. https://products.mhra.gov.uk. Accessed 11/04/2023.

Disclaimer: This information is independently developed by MIMS based on Bromfenac from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in